Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, provides guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $54.70 +1.30%
EPS Growth %: +10.3%
Financial Fact:
Net Sales: 4.92B
Today's EPS Names:
JFIN, KEQU, LASE, More
EPS Growth %: +10.3%
Financial Fact:
Net Sales: 4.92B
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $2.07, $0.43 better than the analyst estimate of $1.64. Revenue for the quarter came in at $12.2 billion versus the consensus estimate of $11.52 billion.
GUIDANCE:
Bristol-Myers Squibb sees Q3 2024 EPS of $0.60-$0.90, versus the consensus of $0.51.
Revenue: Upper end of low single- digit range
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
- Jefferies Reinstates Talen Energy (TLN) at Hold
- Omnicom launches Acxiom Fan Graph sports marketing platform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
